Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib in HER2-mutant metastatic or unresectable solid tumors
2024-517419-62-00Phase 2Authorised
- Sponsor
- Bayer
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of sevabertinib in Nonhematologic neoplasms, colorectal cancer (CRC), biliary cancer and 5 more, sponsored by Bayer. Primary endpoint: Objective response rate. Planned start Feb 2025; status: authorised.
02
Drugs
sevabertinib
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)biliary cancerbladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-517419-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517419-62-00.